tirzepatide pediatrics Tirzepatide's Association With BP Reduction Reinforced With ABPM Data Tirzepatide Once Weekly in Children

The semaglutide and the combination-therapy group had semaglutide treatment for 16 weeks and then had either tablet placebo or empagliflozin added to the treatment, respectively, for a further 16 weeks

Available Now

Conclusions Once-weekly semaglutide 0.5 mg and 1 mg were considered dominant (more effective and less costly) versus sitagliptin 100 mg and dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on oral anti-hyperglycemic medications and are likely to be a good use of healthcare resources in the Spanish setting.

Research Use Only: This product is supplied strictly for in-vitro laboratory and analytical research purposes only

PlexusDx helps determine your optimal treatment timeline with personalized GLP-1 protocols

Active Ingredient Semaglutide (Advanced GLP-1 Receptor Agonist) Cartridge Concentration 15 mg Semaglutide per 3ml Cartridge (5 mg/mL) Delivery Tool Semaglyn Reusable Customized Precision Injector Pen Primary Manufacturer Zydus Healthcare Limited Administration Route Subcutaneous Injection (Weekly adjustable baseline) Kit Components 1 Cartridge + 1 Reusable Pen + 10 Sterile Needles Primary Indication Chronic Anti-Obesity Management & Type 2 Diabetes Support